The effect of selenium administered acutely or chronically on the hepatic microsomal drug-metabolizing system has been investigated in mice. After 72 h following acute administration of selenium (7.5 mg/kg, i.p.), there was a significant inhibition of the activities of aminopyrine (AM) N-demethylase and ethylmorphine (EM) N-demethylase, and cytochrome P-450 levels but no change in the activities of aniline (AN) hydroxylase, 7-ethoxycoumarin (EC) O-deethylase, reduced nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome c reductase and reduced nicotinamide adenine dinucleotide (NADH)-ferricyanide reductase, and cytochrome b5 content. Chronic administration of selenium in the drinking water (1 or 2 ppm selenium) for 12 weeks, resulted in no alteration in any of the parameters measured. However, significant decreases in activities of AM N-demethylase and AN hydroxylase, and cytochrome P-450 levels were detected in animals given higher doses of selenium (4 or 8 ppm selenium). Following the in vitro additions of selenium to hepatic microsomes obtained from untreated mice, selenium inhibited the AM N-demethylase, AN hydroxylase and 7-EC O-deethylase in a concentration-dependent manner, but no alteration in NADPH-cytochrome c reductase and cytochrome P-450 levels was observed. These results indicate that selenium is a specific from inhibitor of hepatic monooxygenase.

Download full-text PDF

Source
http://dx.doi.org/10.1248/bpb1978.15.377DOI Listing

Publication Analysis

Top Keywords

cytochrome p-450
12
p-450 levels
12
selenium
10
mice acute
8
administration selenium
8
reduced nicotinamide
8
nicotinamide adenine
8
adenine dinucleotide
8
nadph-cytochrome reductase
8
reductase cytochrome
8

Similar Publications

Differential detoxification enzyme profiles in C-corn strain and R-rice strain of Spodoptera frugiperda by comparative genomic analysis: insights into host adaptation.

BMC Genomics

January 2025

Provincial Key Laboratory for Agricultural Pest Management of Mountainous Region, Institute of Entomology, Guizhou University, Guiyang, 550025, China.

Background: The fall armyworm (FAW) Spodoptera frugiperda, a highly invasive, polyphagous pest, poses a global agricultural threat. It has two strains, the C-corn and R-rice strains, each with distinct host preferences. This study compares detoxification enzyme gene families across these strains and related Spodoptera species to explore their adaptation to diverse host plant metabolites.

View Article and Find Full Text PDF

Background And Purpose: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease characterized by abnormal bile acid synthesis. It often presents with systemic and neurological manifestations; however, atypical presentations can lead to significant diagnostic challenges. This case report highlights the diagnostic complexities and management considerations in a patient with an uncommon presentation of CTX.

View Article and Find Full Text PDF
Article Synopsis
  • Uremic patients accumulate protein-bound uremic toxins (PBUTs), which alter drug metabolism by affecting the environment around liver cells and CYP450 enzymes.
  • The study found that specific PBUTs like indoxyl sulfate (IS) and hippurate (HA) significantly inhibit the metabolism of atorvastatin (ATV), with IS being the most impactful, reducing ATV metabolism by over 50%.
  • Results showed that the expression of the enzyme CYP3A4, critical for drug metabolism, was downregulated in the presence of uremic serum, leading to decreased ATV uptake and excretion due to effects on related signaling pathways.
View Article and Find Full Text PDF

An aberrant pro-inflammatory microglia response has been associated with most neurodegenerative disorders. Identifying microglia druggable checkpoints to restore their physiological functions is an emerging challenge. Recent data have shown that microglia produce de novo neurosteroids, endogenous molecules exerting potent anti-inflammatory activity.

View Article and Find Full Text PDF

[Precision Medicine for Patients with Renal Cell Carcinoma Based on Drug-metabolizing Enzyme Expression Levels].

Yakugaku Zasshi

January 2025

Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

Notable advances have recently been achieved in drug therapies for renal cell carcinoma (RCC). Several tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have been approved for metastatic RCC (mRCC). The current first-line treatment for mRCC involves combination therapies using TKIs and ICIs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!